Search CatalystAlert
Search for companies, drugs, and catalysts
Search CatalystAlert
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No catalyst events have been recorded for this drug yet.
0 competitors in Monocarboxylate Transporter 8 Deficiency
View Full LandscapeTarget Indication
Monocarboxylate Transporter 8 Deficiency
Clinical Trial
NCT05579327Last updated: 6/26/2026
No patent data available. Pre-approval drugs may not have Orange Book listings.
Emcitate
Emcitate is indicated for the treatment of peripheral thyrotoxicosis in patients with monocarboxylate transporter 8 (MCT8) deficiency (Allan-Herndon-Dudley Syndrome), from birth.